CEN Biotech Profit Margin

The latest profit margin for CENBF is -119.64% as of September 2023. That compares with -223.99% in the prior-year period — up 46.6% year over year. That is below the sector sector average of 13.2%. Investors often review this figure alongside CEN Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, CENBF's profit margin moved from -223.99% to -119.64% — a 46.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CEN Biotech's valuation or profitability profile.

Against its sector companies, CENBF currently prints -119.64% for profit margin, while the sector average sits near 13.2%. That is roughly 1006.4% below the sector mean. Large gaps often invite a closer look at CEN Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively CEN Biotech converts resources into returns. At -119.64%, CENBF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -223.99% in the prior-year period — up 46.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CENBF's profit margin (-119.64%), review year-over-year change from -223.99%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.